» Articles » PMID: 37092469

Computational Screening of Approved Drugs for Inhibition of the Antibiotic Resistance Gene in Methicillin-Resistant (MRSA) Strains

Overview
Journal BioTech (Basel)
Specialty Biotechnology
Date 2023 Apr 24
PMID 37092469
Authors
Affiliations
Soon will be listed here.
Abstract

Antibiotic resistance is a critical problem that results in a high morbidity and mortality rate. The process of discovering new chemotherapy and antibiotics is challenging, expensive, and time-consuming, with only a few getting approved for clinical use. Therefore, screening already-approved drugs to combat pathogens such as bacteria that cause serious infections in humans and animals is highly encouraged. In this work, we aim to identify approved antibiotics that can inhibit the antibiotic resistance gene found in methicillin-resistant (MRSA) strains. The MecA protein sequence was utilized to perform a BLAST search against a drug database containing 4302 approved drugs. The results revealed that 50 medications, including known antibiotics for other bacterial strains, targeted the antibiotic resistance gene. In addition, a structural similarity approach was employed to identify existing antibiotics for , followed by molecular docking. The results of the docking experiment indicated that six drugs had a high binding affinity to the antibiotic resistance gene. Furthermore, using the structural similarity strategy, it was discovered that afamelanotide, an approved drug with unclear antibiotic activity, had a strong binding affinity to the MRSA-MecA protein. These findings suggest that certain already-approved drugs have potential in chemotherapy against drug-resistant pathogenic bacteria, such as MRSA.

Citing Articles

Structural characteristics, functions, and counteracting strategies of biofilms in .

Xia Y, Hu Z, Jin Q, Chen Q, Zhao C, Qiang R Comput Struct Biotechnol J. 2025; 27:488-500.

PMID: 39916696 PMC: 11799891. DOI: 10.1016/j.csbj.2025.01.021.


Advances in genotypic antimicrobialresistance testing: a comprehensive review.

Duan B, Zeng X, Peng J Sci China Life Sci. 2024; 68(1):130-143.

PMID: 39300049 DOI: 10.1007/s11427-023-2570-4.


The Prevalence, Epidemiological, and Molecular Characterization of Methicillin-Resistant (MRSA) in Macau (2017-2022).

Xing A, Ng H, Jiao H, Li K, Ye Q Microorganisms. 2024; 12(1).

PMID: 38257975 PMC: 10820975. DOI: 10.3390/microorganisms12010148.

References
1.
Zhanel G, Schweizer F, Karlowsky J . Oritavancin: mechanism of action. Clin Infect Dis. 2012; 54 Suppl 3:S214-9. DOI: 10.1093/cid/cir920. View

2.
de Vries H, de Laat M, Jongen V, Heijman T, Wind C, Boyd A . Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis. 2022; 22(5):706-717. DOI: 10.1016/S1473-3099(21)00625-3. View

3.
Miller B, Hershberger E, Benziger D, Trinh M, Friedland I . Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012; 56(6):3086-91. PMC: 3370713. DOI: 10.1128/AAC.06349-11. View

4.
Hayashi Y, Roberts J, Paterson D, Lipman J . Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol. 2010; 6(8):1017-31. DOI: 10.1517/17425255.2010.506187. View

5.
Kampf G, Jarosch R, Ruden H . Limited effectiveness of chlorhexidine based hand disinfectants against methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect. 1998; 38(4):297-303. DOI: 10.1016/s0195-6701(98)90078-0. View